Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Exact Sciences Corp - SIC # 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
EXAS
Nasdaq
2835
http://www.exactsciences.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Exact Sciences Corp
Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?
- Mar 28th, 2024 3:30 pm
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
- Mar 28th, 2024 10:00 am
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner
- Mar 27th, 2024 12:05 pm
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
- Mar 26th, 2024 1:00 pm
How Much Upside is Left in Exact Sciences (EXAS)? Wall Street Analysts Think 53.83%
- Mar 25th, 2024 1:55 pm
Here's How Much You'd Have If You Invested $1000 in Exact Sciences a Decade Ago
- Mar 25th, 2024 12:30 pm
Exact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue?
- Mar 22nd, 2024 3:30 pm
Exact Sciences Corporation (NASDAQ:EXAS) is largely controlled by institutional shareholders who own 89% of the company
- Mar 21st, 2024 2:36 pm
Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM
- Mar 18th, 2024 12:19 pm
Guardant posts data for colon cancer blood test amid push from rivals
- Mar 18th, 2024 8:30 am
Cathie Wood Darling Exact Sciences, And Rival Guardant Health, Dip On Colon Cancer Updates
- Mar 14th, 2024 8:16 pm
The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study
- Mar 13th, 2024 9:03 pm
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
- Mar 11th, 2024 2:36 pm
2 Beaten-Down Cathie Wood Stocks With Massive Potential
- Mar 11th, 2024 4:59 am
Can Exact Sciences (EXAS) Climb 55.43% to Reach the Level Wall Street Analysts Expect?
- Mar 8th, 2024 2:55 pm
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
- Mar 8th, 2024 12:31 pm
Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer
- Mar 7th, 2024 12:59 pm
Exact Sciences Corp (EXAS) Director Daniel Levangie Sells 5,000 Shares
- Mar 5th, 2024 4:52 am
The Top 3 Healthcare Stocks to Buy on Weakness in 2024
- Mar 4th, 2024 8:49 pm
7 Stable Stocks to Buy for 100% Returns by 2025
- Mar 4th, 2024 3:38 pm
Scroll